Neurotrack is transforming the diagnosis of Alzheimer’s disease. Through a safe and non-invasive test, its technology can predict the risk of developing mild cognitive impairment and Alzheimer’s disease years before symptoms occur. Conceived at Emory University and validated by a 5-year study funded by the National Institutes of Health (NIH), it will give pharmaceutical companies better tools to recruit patients for clinical trials, leading to the development of life-saving drugs.

Neurotrack is backed by Founders Fund and Social + Capital, and was the winner of more than $7M in grants from the NIH. It was named Best Health Company at SXSW, DEMO, and participated in the Rock Health accelerator.

Palo Alto, US
16 (est)+24%
Neurotrack was founded in 2012 and is headquartered in Palo Alto, US

Neurotrack Locations

Palo Alto, US

Neurotrack Metrics

Neurotrack Summary

Founding Date


Total Funding

$9.59 M

Latest funding size

$6.5 M

Time since last funding

12 months


We estimate that Neurotrack's latest funding round in January 2016 was $6.5 M. In total, Neurotrack has raised $9.59 M
We estimate that Neurotrack's current employees are approximately 42% female and 58% male.

Neurotrack Online Presence

Neurotrack News

Neurotrack Company Life

You may also be interested in